PMC:7195088 / 66201-66604 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1895","span":{"begin":168,"end":176},"obj":"Species"},{"id":"1900","span":{"begin":182,"end":190},"obj":"Disease"},{"id":"1925","span":{"begin":15,"end":25},"obj":"Species"},{"id":"1928","span":{"begin":86,"end":93},"obj":"Chemical"},{"id":"1929","span":{"begin":157,"end":164},"obj":"Chemical"}],"attributes":[{"id":"A1895","pred":"tao:has_database_id","subj":"1895","obj":"Tax:9606"},{"id":"A1900","pred":"tao:has_database_id","subj":"1900","obj":"MESH:C000657245"},{"id":"A1925","pred":"tao:has_database_id","subj":"1925","obj":"Tax:2697049"},{"id":"A1928","pred":"tao:has_database_id","subj":"1928","obj":"MESH:C558899"},{"id":"A1929","pred":"tao:has_database_id","subj":"1929","obj":"MESH:C558899"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T380","span":{"begin":15,"end":23},"obj":"Disease"},{"id":"T381","span":{"begin":182,"end":190},"obj":"Disease"}],"attributes":[{"id":"A380","pred":"mondo_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T367","span":{"begin":306,"end":308},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T368","span":{"begin":399,"end":401},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94861","span":{"begin":341,"end":345},"obj":"Chemical"}],"attributes":[{"id":"A96374","pred":"chebi_id","subj":"T94861","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T469","span":{"begin":0,"end":403},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]."}

{"project":"2_test","denotations":[{"id":"32360444-32187464-22369823","span":{"begin":399,"end":401},"obj":"32187464"}],"text":"With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]."}